NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE). Those investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, extension 7980.

The investigation concerns whether Ampio and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

During premarket hours on August 3, 2022, Ampio issued a press release with a letter to shareholders stating that Ampio executives were aware at the time of a protocol-related interim analysis in March 2020 that the Company’s AP-013 clinical study was being conducted its product Ampion failed to demonstrate efficacy on its co-primary endpoints of pain and function; and that Company executives have not fully reported the results of the AP-013 study and the timing of the unblinding of the AP-013 study data.

As a result of this news, Ampio’s share price fell $0.06, or 35.38%, to close at $0.10 per share on August 3, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com

CONTACT:
Robert S Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980